Sagent Pharmaceuticals, Inc. (SGNT) Misses Q1 EPS by 2c
Get Alerts SGNT Hot Sheet
Join SI Premium – FREE
Sagent Pharmaceuticals, Inc. (NASDAQ: SGNT) reported Q1 EPS of ($0.30), $0.02 worse than the analyst estimate of ($0.28). Revenue for the quarter came in at $38.3 million versus the consensus estimate of $42.31 million.
For earnings history and earnings-related data on Sagent Pharmaceuticals, Inc. (SGNT) click here.
For earnings history and earnings-related data on Sagent Pharmaceuticals, Inc. (SGNT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Top AI Semiconductor Stocks According to Stifel Analysis
- Jet fuel prices near $5 per gallon in New York and Los Angeles
- TD Cowen on Pepsico (PEP): 'Ongoing Weakness in North America Drives Guidance Cut'
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share